Navigation Links
ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Date:1/6/2009

PARIS, France, January 6 /PRNewswire-FirstCall/ --

- Early Renewal of the Agreement to Extend the Collaboration Until December 2011

- Expansion of the Scope of the Collaboration to Include Antibody Discovery in Ophthalmology

- Revised Commercial Terms and Payments to ExonHit if Allergan Sublicenses to a Third Party

ExonHit Therapeutics (Alternext: ALEHT) today announced a reinforcement of its existing drug discovery collaboration with Allergan Sales, LLC (NYSE: AGN). The collaboration is extended until December 2011, includes antibody discovery within the scope of the research activities and encompasses revised commercial terms.

The collaboration which has been renewed several times and initiated in December 2002 focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology. EHT/AGN 0001, the most advanced compound out of the collaboration, is currently ending Phase I clinical trials for pain indications. EHT/AGN 0002 and other compounds are in pre-clinical testing for indications in pain, ophthalmology or neurodegenerative diseases.

Allergan exercised its option to extend this collaboration until December 2011 earlier than anticipated. As part of the renewal agreement, Allergan will provide ExonHit with increased quarterly research funding instead of a single payment.

The scope of the collaboration is expanded to include epitope* discovery for the development of antibody therapeutics in ocular disorders. ExonHit's unique gene profiling technology can readily be applied to identify disease specific target proteins, but also pinpoints novel epitopes present in those proteins, which are produced via alternative splicing. ExonHit's approach offers the potential be
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Commenting on GSK,s Q2 performance, ... Simon Dingemans reveals sales rose during the period ... with expectations. Ahead of a November R&D update day ... The interview and transcript are available now on ... documentaries and webcasts with senior company executives. If you ...
(Date:7/29/2015)... 2015 Cogentix Medical, Inc. (NASDAQ: CGNT ), ... will release financial results for the first quarter of fiscal ... close on Monday, August 10, 2015. The ... these results on Monday, August 10, 2015 at 4:30 p.m. ... President and Chief Executive Officer, and Brett Reynolds , ...
(Date:7/29/2015)... Calif. , July 29, 2015  Cepheid ... availability of an update to Xpert® Carba-R, with ... OXA-181 and OXA-232.  The on-demand, molecular test also ... mechanisms of carbapenem resistance, namely KPC, NDM, VIM, ... referred to as CROs or Superbugs, are a ...
Breaking Medicine Technology:Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, Inc., announces ... Relief and Healing Cream designated as the nonprofit’s natural pain reliever of choice.     ... Line of Duty Deaths (LODD) and the high rate of pain and injuries ...
(Date:7/29/2015)... , ... July 29, 2015 , ... This year, the ... precipitation levels this spring. And, where there is water, mold is not far behind. ... offers tips for protecting against water and mold damage. Paul Davis is regularly called ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Southwest Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , ... http://www.kalamazoosc.com , and “reflects the evolution of our training center over the past ...
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical Center ... Medical Rotator Cuff System, a new implant to treat a common source of shoulder ... natural regeneration of additional tendon tissue, which could allow for faster healing and a ...
(Date:7/29/2015)... ... 29, 2015 , ... Wedding season is in full swing, which means bridal beauty prep is ... good on the big day. Every bride wants to look and feel beautiful, but a ... According to a recent study by the American Academy of Facial Plastic ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... improved sleep for patients with chronic neck or back ... interfered with their daily functioning, according to a study ... study, published online by the journal Sleep Medicine, ... who already are taking medications for pain and might ...
... , OMAHA, Neb. , Feb. 11 ... dental technology developed to improve human dental health for two ... Cleaning Paste and the Petrodex® Tooth-Hugger Toothbrush. The Petrodex Tooth-Hugger ... Petrodex Ultra Advanced Veterinary Cleaning Paste will be available in ...
... , Idiopathic Pulmonary Fibrosis (IPF) ... SAN JOSE, Calif. , Feb. 11 ... Commissioner Michael Astrue ,s announcement this morning via press ... Fibrosis (PF), and a listing of 37 other diseases and ...
... PITTSBURGH, Feb. 11 Patients admitted to hospitals with ... hospitals with low-intensity approaches, according to a University of ... issue of the journal Medical Care. Higher-intensity care refers ... admission, intubation or mechanical ventilation, kidney dialysis and feeding ...
... finds less than 1% use it as preventative; experts say drug ... -- Only a tiny fraction of women at high risk of ... This news comes despite the fact that experts have known since ... by almost 50 percent. , "This is not a surprise to ...
... ... FAB-HOMES ™, a green home design studio based in Vancouver, Canada, is ... market. Fab-homes™ showcases a selection of modern, European dwellings planned along the ... 90% less energy for heating, cooling and building operation than a standard ...
Cached Medicine News:Health News:Behavioral therapy improves sleep and lives of patients with pain 2Health News:Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeant's Pet Care Products, Inc. 2Health News:Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeant's Pet Care Products, Inc. 3Health News:Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration 2Health News:Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration 3Health News:Survival benefit with high-intensity end-of-life approaches 2Health News:Few Women at High Risk for Breast Cancer Take Tamoxifen 2Health News:Few Women at High Risk for Breast Cancer Take Tamoxifen 3Health News:FAB-HOMES™ Presents First Passive House Collection 2Health News:FAB-HOMES™ Presents First Passive House Collection 3
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540, 0887....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasmawith heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all free...
Medicine Products: